Wordt geladen...
A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose escalation study of tipifarnib, an oral FT inhibitor, in patients with relapsed, refractory, or newly diagnosed (if over age 70) acute myeloge...
Bewaard in:
Hoofdauteurs: | , , , , , , , , , , , , , |
---|---|
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
2011
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3165084/ https://ncbi.nlm.nih.gov/pubmed/21625235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.124 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|